Atlas Trials

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Clinical trial NCT04372433 · COMPLETED

Trial details

NCT number
NCT04372433
Sponsor
Immune-Onc Therapeutics
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
AML With Monocytic DifferentiationCMML
Start date
2020-09-14
Primary completion
2025-01-31
Enrollment
67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.